Skip to main content
News08 Dec 2023

New Chair for Garvan Institute of Medical Research

We are pleased to announce the appointment of Mr Scott Perkins as Chair of Garvan's Board of Directors.

Garvan Institute of Medical Research is pleased to announce the appointment of Mr Scott Perkins as the incoming Chair of the Board of Directors.

Mr Perkins is a leading Australian Company Director serving as Chair of Woolworths Group and Origin Energy and a Director of Brambles.

He has a long-standing commitment to the not-for-profit sector across a broad range of public health, public policy and visual arts organisations. He also served, for 14 years, as a Director of Uniservices, the research commercialisation arm of Auckland University. Mr Perkins lives in Sydney with his wife Yael and two children.

“Scott is a true leader in the Australian business community and a passionate advocate for the importance of medical research. I couldn’t be more pleased to announce him as my successor,” says outgoing Chair, Dr John Schubert AO.

Additionally, Mr Perkins has a long history of supporting cancer research and care. He is founder and Chair of Sweet Louise, a charity established in 2006 in memory of his late wife who passed away from breast cancer in 2004. Sweet Louise provides practical, emotional, and social care and support for New Zealanders living with incurable breast cancer.

“I’ve long admired the remarkable work of the Garvan Institute of Medical Research and its pioneering research. As for many in the community, Garvan’s work is a cause that is very close to my heart. It is an honour to take on the role of Chair, and I look forward to meeting our people, partners and generous donors over the coming months and working to support Ben and the team to fulfill Garvan’s immense potential,” says Mr Perkins.

Departing Chair, Dr John Schubert AO, retires following more than 10 years in the role and two decades of involvement. During this time, he has steered the organisation through great change and challenge and leaves Garvan in a position of significant strength, renewal, and international standing.

“John’s tenure has included oversight of three Executive Directors and the unprecedented challenges of a global pandemic. Under his leadership, Garvan has cemented its position as a global leader in cancer, immunology and genomics, whilst serving the community through its mission to deliver improved diagnostics, targeted treatments and tangible clinical impact,” says Garvan’s Executive Director, Professor Benjamin Kile. “I am extraordinarily grateful for his dedication to, and support of, Garvan over these many years. Personally, he has been a generous and astute guide as I’ve integrated into the Institute.”

The appointment will take effect 9 December 2023.